Famous Patents
William F. Semple, a dentist, was awarded the first US Patent on chewing gum in 1869. His recipe contained powdered chalk.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6090544 | Methods and compositions for identifying morphogen analogs Disclosed herein are methods and compositions for identifying morphogen analogs. The preferred methods and compositions relate to the discovery that morphogen upregulation of the mouse type X collagen promoter activity is mediated by a MEF-2 like sequence... | 07/18/2000 |
| 6071695 | Methods and products for identification of modulators of osteogenic protein-1 gene expression Disclosed are methods and compositions for screening compounds for their ability to modulate expression of a tissue morphogenetic protein, particularly OP-1, OP-1 homologs and closely related proteins, using one or more OP-1-specific, noncoding nucleotide... | 06/06/2000 |
| 5994131 | Morphogenic protein screening method Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture k... | 11/30/1999 |
| 5972884 | Morphogen treatment of gastrointestinal ulcers Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation no... | 10/26/1999 |
| 5968752 | Method for identifying an OP-1 analog which binds an ALK-1 receptor Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features, and various other data characterizing morphogen cell surface receptors, particularly OP-1-binding cell surface receptors, e.g., ALK-1; (2) methods for produci... | 10/19/1999 |
| 5932716 | Morphogen-responsive regulatory elements Disclosed herein are methods and compositions for identifying morphogen analogs. Preferred methods rest on the use of test cells comprising DNA defining a morphogen-responsive transcription activating element operatively associated with a reporter gene. I... | 08/03/1999 |
| 5906827 | Matrix for the manufacture of autogenous replacement body parts Disclosed are matrices, devices and methods for the manufacture of live autogenous skeletal replacement parts comprising plural different tissues.... | 05/25/1999 |
| 5877305 | DNA encoding biosynthetic binding protein for cancer marker Disclosed is DNA encoding a single-chain Fv (sFv) polypeptide defining a binding site which exhibits the immunological binding properties of an immunoglobulin molecule which binds c-erbB-2 or a c-erbB-2-related tumor antigen, the sFv includes at least two... | 03/02/1999 |
| 5863738 | Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptors particularey OP-1-binding cell surface receptors; (2) methods for producing receptor p... | 01/26/1999 |
| 5861479 | Morphogen cell surface receptor Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptor; (2) methods for producing receptor proteins, including fragments thereof, using recomb... | 01/19/1999 |
| 5861156 | Methods of delivering agents to target cells Methods of delivering agents to target cells including methods of immunotherapy, are disclosed in which monospecific binding proteins are administered to a host and bind to target cells followed by administration of multivalent antibodies to direct the ag... | 01/19/1999 |
| 5837846 | Biosynthetic binding proteins for immuno-targeting Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosy... | 11/17/1998 |
| 5834179 | Morphogenic protein compositions of matter Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.... | 11/10/1998 |
| 5834188 | Methods and compositions for identifying morphogen analogs Disclosed herein are methods and compositions for identifying morphogen analogs. Preferred methods rest on the use of test cells comprising DNA defining a morphogen-responsive transcription activating element operatively associated with a reporter gene. I... | 11/10/1998 |
| 5831050 | Morphogen cell surface receptor Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptor; (2) methods for producing receptor proteins, including fragments thereof, using recomb... | 11/03/1998 |
| 5759815 | Production of platelet derived growth factor (PDGF) an muteins thereof Native, analog, and mutein species of A and B chains of platelet derived growth factor are produced in prokaryotes, purified, combined, and modified in vitro to produce various active AA, AB, and BB PDGF dimers.... | 06/02/1998 |
| 5753204 | Biosynthetic binding proteins for immunotargeting Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosy... | 05/19/1998 |
| 5741641 | Morphogenic protein screening method Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture k... | 04/21/1998 |
| 5739107 | Morphogen treatment of gastrointestinal ulcers Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation no... | 04/14/1998 |
| 5733782 | Methods and compositions for high protein production from non-native DNA Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creat... | 03/31/1998 |
| 5733878 | Morphogen-induced periodontal tissue regeneration Disclosed are methods and compositions for inducing periodontal tissue morphogenesis in a mammal which include a therapeutically effective concentration of a morphogen. The methods and compositions are useful for integrating an implanted tooth in a tooth ... | 03/31/1998 |
| 5712119 | Methods and compositions for high protein production form recombinant DNA Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creat... | 01/27/1998 |
| 5707810 | Method of diagnosing renal tissue damage or disease In one aspect, the present invention provides a method of diagnosing renal tissue damage or disease by measuring endogenous expression of OP-1 by renal tissue of a mammal (e.g., a human) in which a depression of endogenous expression relative to undamaged... | 01/13/1998 |
| 5700677 | Protein analogues of tissue plasminogen activator Protein analogues of tissue plasminogen activator (tPA) are described. The analogues exhibit the proteolytic function of natural tPA and optionally fibrin binding activity, but are molecules, generally of lower molecular weight than natural tPA, designed ... | 12/23/1997 |
| 5674844 | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulat... | 10/07/1997 |
| 5658763 | Methods and compositions for high protein production from non-native DNA Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creat... | 08/19/1997 |
| 5656593 | Morphogen induced periodontal tissue regeneration Disclosed are methods and compositions for inducing periodontal tissue morphogenesis in a mammal which include a therapeutically effective concentration of a morphogen. The methods and compositions are useful for integrating an implanted tooth in a tooth ... | 08/12/1997 |
| 5652118 | Nucleic acid encoding a novel morphogenic protein, OP-3 Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mamm... | 07/29/1997 |
| 5652337 | OP-3-induced morphogenesis Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mamm... | 07/29/1997 |
| 5650276 | Morphogenic protein screening method Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture k... | 07/22/1997 |
| 5631159 | Lipid-modified serum free media Methods are provided for producing serum-free, animal cell culture media which have enhanced cell culture properties, such as cell growth, cell viability and protein production properties. The cell culture properties of standard serum-free media formulati... | 05/20/1997 |
| 5631158 | Methods and compositions for high protein production from non-native DNA Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creat... | 05/20/1997 |
| 5614385 | Methods and compositions for high protein production from recombinant DNA Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creat... | 03/25/1997 |
| 5610021 | Compositions and methods for identification and use of soluble complex forms of osteogenic proteins Disclosed are novel compositions of osteogenic proteins constituting soluble forms of these proteins, and methods and compositions for distinguishing between soluble and mature forms of these proteins.... | 03/11/1997 |
| 5585237 | Methods and compositions for high protein production from recombinant DNA Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creat... | 12/17/1996 |
| 5534254 | Biosynthetic binding proteins for immuno-targeting Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosy... | 07/09/1996 |
| 5525491 | Serine-rich peptide linkers Disclosed are serine-rich peptide linkers for linking two or more protein domains to form a fused protein. The peptide linkers contains at least 40% serine residues and preferably have the formula (Ser, Ser,Ser,Ser,Gly)y where y is ࣙ1. The re... | 06/11/1996 |
| 5482858 | Polypeptide linkers for production of biosynthetic proteins Disclosed are a family of synthetic proteins having binding affinity for a preselected antigen, and multifunctional proteins having such affinity. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves a... | 01/09/1996 |
| 5476786 | Biosynthetic antibody binding sites Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites co... | 12/19/1995 |
| 5418135 | Method of inhibiting binding of PDGF to a PDGF receptor by biosynthetic PDGF antagonists Disclosed are polypeptides which antagonize the activity of platelet-derived growth factor (PDGF). These polypeptides include an amino acid sequence sufficiently duplicative of at least a portion of the amino acid sequence of an A chain of PDGF such that ... | 05/23/1995 |
